Latest Articles

Publication Date
Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …

Published: Feb. 6, 2025, midnight
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
The effect of dienogest and gonadotropin-releasing hormone agonist on pelvic pain after laparoscopic surgery for endometriosis: An RCT.

Endometriosis is a chronic inflammatory condition associated with debilitating chronic pelvic pain that affects women's quality of life. Several drugs have been used to reduce pain and psychological distress associated …

Published: Jan. 31, 2025, midnight
A rare case of extrapelvic endometriosis in the right sciatic notch.

Endometriosis is described as the proliferation of endometrial tissue outside of the uterus. This most frequently occurs within the pelvis and is a common cause of chronic pelvic pain in …

Published: Dec. 31, 2024, midnight
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial …

Published: Dec. 31, 2024, midnight
Recent Trends in Medical Management of Endometriosis.

Endometriosis affects about 10 percent women in the reproductive age group globally and approximately 42 million in India. Managing the patient's pain symptoms associated with endometriosis appears to be the …

Published: Dec. 26, 2024, midnight
A Case of Familial Mediterranean Fever With Severe Attacks During Withdrawal Bleeding After Controlled Ovarian Hyperstimulation.

Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever, serositis, and arthritis. In women, FMF attacks can sometimes be triggered by the menstrual cycle. Once diagnosed, prophylactic …

Published: Dec. 21, 2024, midnight
Kisspeptin and Endometriosis-Is There a Link?

This article presents a narrative review that explores the potential link between kisspeptin-a key regulator of the hypothalamic-pituitary-gonadal axis-and the pathogenesis of endometriosis. Kisspeptin plays a significant role in regulating …

Published: Dec. 17, 2024, midnight
Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies.

Endometriosis is a chronic, inflammatory disease characterized by the presence of endometrial-like tissue outside the uterus, affecting women of reproductive age. It is linked with debilitating pain, infertility, and a …

Published: Dec. 12, 2024, midnight
A Case of Early-Stage Lower Uterine Segment Carcinoma With Hysteroscopic Observation of Visual Changes Induced by a Gonadotropin-Releasing Hormone (GnRH) Antagonist - Cureus

A Case of Early-Stage Lower Uterine Segment Carcinoma With Hysteroscopic Observation of Visual Changes Induced by a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cureus

Published: Nov. 23, 2024, 11:41 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!